Loading...
XNAS
MGRX
Market cap3mUSD
Jul 09, Last price  
0.37USD
1D
4.12%
1Q
10.06%
IPO
-87.73%
Name

Mangoceuticals Inc

Chart & Performance

D1W1MN
XNAS:MGRX chart
P/E
P/S
8.32
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
456k
-25.96%
08,939731,493615,873456,021
Net income
-21m
L+137.12%
-17,701-1,998,055-9,212,417-8,706,000-20,643,455
CFO
-6m
L+20.28%
-17,520-1,346,518-6,997,375-4,863,776-5,850,255

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.
IPO date
Mar 21, 2023
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT